Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT05441826 is registered in ClinicalTrials.gov with Tenet Medicines as lead sponsor.

NCT NCT05441826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05441826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)
Lead sponsor
Tenet Medicines
Phase
Phase 2
Overall status
Terminated
Start date
May 3, 2022
Completion date
October 12, 2023
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis, minimal change disease